Matthew Willmott

PhD Candidate at the University of Manchester @Turner_Biocat

[Gareth Surman @GRESurman]

Some job news - pleased to say that I have joined @Melchiorre_P @MelchiorreGroup at the University of Bologna! I’m very excited to start this new chapter as part of the ERC AdG PHOTOZYME project, looking forwards to some very exciting photobiocatalysis projects 💡

[Matthew Willmott @MJWillmott_]

Very happy to have published my first first-author paper in @NatureSynthesis. Huge thanks to @Turner_Biocat and everyone involved!

[Nature Synthesis @NatureSynthesis]

Now online and open access:

Article by @MJWillmott_, Nicholas J. Turner & co-workers @Turner_Biocat @UoMChemistry @AstraZeneca

An engineered aldolase enables the biocatalytic synthesis of 2′-functionalized nucleoside analogues

https://t.co/maxvRFRlEI

[Turner Biocatalysis @Turner_Biocat]

🚨 New preprint!

Our preprint 'A biocatalytic platform for the synthesis of 2′-functionalized nucleoside analogues' is available to read now on @ChemRxiv!

https://t.co/KuA4zUIviz

@MJWillmott_ @willfinnigan @Ch_Schnepel @RachelHeath82 @AstraZeneca

[Matthew Willmott @MJWillmott_]

@cjrw @uniofleicester When I was young all this used to be fields

[Royal Society of Chemistry @RoySocChem]

1 year on, there are 4 #CovidVaccine licenced for use across the world, all of which use part of the virus RNA sequence, with many more in clinical trials. Our previous graphics with @CompoundChem explain how the genetic sequence is used in RNA and viral vector #vaccines